A small Phase I/II study of Prothena’s lead drug produced an encouraging round of initial responses among patients with AL amyloidosis, a rare threat to organs. And now company execs say they’re going straight into a Phase III study of NEOD001 so they can build a case for regulators.

…read more

Source: Prothena gets a positive snapshot of efficacy for rare disease drug, preps for PhIII


0 No comments